Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutic Development Review, H2 2015

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects.

Get a copy of this report at . This is a premium report price at US$2000 for a single user PDF license

Companies Mentioned in report are Arisaph Pharmaceuticals, Inc., Conatus Pharmaceuticals Inc., Daewoong Pharmaceutical Co., Ltd., Dimerix Bioscience Pty Ltd, Dr. Falk Pharma GmbH, DURECT Corporation, Galmed International Ltd., Gilead Sciences, Inc., Huons Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Metabolic Solutions Development Company, LLC, Novartis AG, Raptor Pharmaceuticals Corp., TCM Biotech International Corp, Tobira Therapeutics, Inc., Verva Pharmaceuticals Limited, Zafgen Inc., Zydus Cadila Healthcare Limited.


- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Non Alcoholic Fatty Liver Disease (NAFLD) and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Non Alcoholic Fatty Liver Disease (NAFLD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.